Genentech, Inc.’s antibody drug conjugate Polivy (polatuzumab vedotin-piiq) has a favorable benefit-risk profile for front-line treatment of diffuse large B-cell lymphoma and should be considered an option, but not necessarily a replacement, for the current highly effective standard of care, US Food and Drug Administration advisory committee members said on 9 March.
Eleven of 13 members of the Oncologic Drugs Advisory Committee looked favorably upon the results from POLARIX, a Phase III trial in which polatuzumab, in combination with R-CHP (rituximab, cyclophosphamide,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?